文献速递临床试验与 GCP流行病学与生物统计

5日呋喃妥因与单剂磷霉素对女性非复杂性下尿路感染临床缓解的随机临床试验

Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

这项跨国开放标签随机试验纳入513例非妊娠女性非复杂性下尿路感染患者,比较口服呋喃妥因100mg每日3次共5天与单剂口服磷霉素3g的疗效。

要点

  • 5日呋喃妥因的28天临床缓解率显著高于单剂磷霉素。
  • 微生物学缓解率呋喃妥因组亦显著优于磷霉素组。
  • 不良事件少,主要为胃肠道反应,两组间差异不大。

核心结论

  • 在非复杂性下尿路感染女性中,5日呋喃妥因较单剂磷霉素在治疗结束后28天临床和微生物学缓解率显著更高。

研究设计与样本

  • 跨国、开放标签、分析者盲法随机临床试验,纳入513例非妊娠女性(年龄≥18岁),1:1随机分组。
  • 呋喃妥因组255例接受口服100mg每日3次共5天;磷霉素组258例接受单剂口服3g。
  • 475例(93%)完成试验,377例(73%)基线培养阳性。

主要发现

  • 不良事件少,主要为胃肠道反应;恶心在呋喃妥因组7/248(3%),磷霉素组5/247(2%);腹泻分别为3/248(1%)和5/247(1%)。

临床怎么用

  • 对于非复杂性下尿路感染女性,5日呋喃妥因方案可考虑作为优先选择之一,以提升临床和微生物学缓解率。

局限性

  • 开放标签设计可能引入偏倚;分析者盲法仅部分控制。
  • 仅有73%患者基线培养阳性,微生物学结果基于该亚组。
  • 试验在三个国家进行,外推性需考虑地区差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The use of nitrofurantoin and fosfomycin has increased since guidelines began recommending them as first-line therapy for lower urinary tract infection (UTI). OBJECTIVE: To compare the clinical and microbiologic efficacy of nitrofurantoin and fosfomycin in women with uncomplicated cystitis. DESIGN, SETTING, AND PARTICIPANTS: Multinational, open-label, analyst-blinded, randomized clinical trial including 513 nonpregnant women aged 18 years and older with symptoms of lower UTI (dysuria, urgency, frequency, or suprapubic tenderness), a positive urine dipstick result (with detection of nitrites or leukocyte esterase), and no known colonization or previous infection with uropathogens resistant to the study antibiotics. Recruitment took place from October 2013 through April 2017 at hospital units and outpatient clinics in Geneva, Switzerland; Lodz, Poland; and Petah-Tiqva, Israel. INTERVENTIONS: Participants were randomized in a 1:1 ratio to oral nitrofurantoin, 100 mg 3 times a day for 5 days (n = 255), or a single 3-g dose of oral fosfomycin (n = 258). They returned 14 and 28 days after therapy completion for clinical evaluation and urine culture collection. MAIN OUTCOMES AND MEASURES: The primary outcome was clinical response in the 28 days following therapy completion, defined as clinical resolution (complete resolution of symptoms and signs of UTI without prior failure), failure (need for additional or change in antibiotic treatment due to UTI or discontinuation due to lack of efficacy), or indeterminate (persistence of symptoms without objective evidence of infection). Secondary outcomes included bacteriologic response and incidence of adverse events. RESULTS: Among 513 patients who were randomized (median age, 44 years [interquartile range, 31-64]), 475 (93%) completed the trial and 377 (73%) had a confirmed positive baseline culture. Clinical resolution through day 28 was achieved in 171 of 244 patients (70%) receiving nitrofurantoin vs 139 of 241 patients (58%) receiving fosfomycin (difference, 12% [95% CI, 4%-21%]; P = .004). Microbiologic resolution occurred in 129 of 175 (74%) vs 103 of 163 (63%), respectively (difference, 11% [95% CI, 1%-20%]; P = .04). Adverse events were few and primarily gastrointestinal; the most common were nausea and diarrhea (7/248 [3%] and 3/248 [1%] in the nitrofurantoin group vs 5/247 [2%] and 5/247 [1%] in the fosfomycin group, respectively). CONCLUSIONS AND RELEVANCE: Among women with uncomplicated UTI, 5-day nitrofurantoin, compared with single-dose fosfomycin, resulted in a significantly greater likelihood of clinical and microbiologic resolution at 28 days after therapy completion. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01966653.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Huttner A, Kowalczyk A, Turjeman A, et al. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA. 2018. PMID: 29710295. doi:10.1001/jama.2018.3627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。